Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 53 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Risedronate Sodium Clear all
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

NCT00577720
View directory record Official record
Conditions
Postmenopausal Women
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Costa Mesa, California • Gainsville, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

NCT00266708
View directory record Official record
Conditions
Renal Transplant Osteodystrophy
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

NCT00377234
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Risedronate, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
48
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Antiepileptic Drugs and Osteoporotic Prevention Trial

NCT00869622
View directory record Official record
Conditions
Epilepsy, Bone Loss, Osteoporosis, Fractures
Interventions
Risedronate, Placebo + Calcium and Vitamin D
Drug
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Sep 30, 2026, 8:02 AM EDT
Completed No phase listed Observational

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

NCT00778154
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Prevention of Osteoporosis in Breast Cancer Survivors

NCT00567606
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

NCT01875458
View directory record Official record
Conditions
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Sep 30, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 30, 2026, 8:02 AM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

NCT00106028
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
risedronate sodium (Actonel), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
4 Years to 15 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837
View directory record Official record
Conditions
Postmenopausal
Interventions
risedronate, experimental
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Monthly Risedronate for Osteoporosis

NCT00247273
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Gainesville, Georgia • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

NCT00717145
View directory record Official record
Conditions
Postmenopausal, Non-lactating, Surgically Sterile
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Sep 30, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

Bone Microarchitecture in Osteopenic Postmenopausal Women

NCT00577395
View directory record Official record
Conditions
Osteoporosis
Interventions
placebo, risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 57 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Tuscon, Arizona • Omaha, Nebraska • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Sep 30, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

NCT00216060
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
31
States / cities
La Mesa, California • San Bernardino, California • New Britain, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 30, 2026, 8:02 AM EDT